Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 14, 2025

Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

PBPeter BramlageAVAnjaly VijayanTVTreesa P. Varghese

Discussion

Loading...

Member takes

Overview

Systematic review finds SGLT2 inhibitors improve renal and cardiovascular outcomes in T2DM with CKD, suggesting they are preferred therapies.

Key Points

  • SGLT2 inhibitors significantly reduce the risk of major adverse cardiovascular events and renal decline in T2DM patients with chronic kidney disease.
  • In a comprehensive network meta-analysis involving 143,296 participants, SGLT2 inhibitors showed a P-score of 0.94 for composite renal outcomes.
  • The analysis included randomized controlled trials published from 2014 to 2024, involving various antidiabetic treatments and their impact on cardiorenal health.
  • Findings indicate that while SGLT2 inhibitors excel in renal and heart failure outcomes, GLP-1 receptor agonists also yield substantial cardiovascular benefits.

Cite This Study

Bramlage et al. (2025) studied this question.

synapsesocial.com/papers/689fc962e46e096235ce1c0bhttps://doi.org/10.1111/dom.70010
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data2026
  2. 2Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs2025
  3. 3Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.2025
  4. 4To evaluate and compare the efficacy of newer antidiabetic medications on cardiovascular outcomes2025
  5. 5SGLT2 inhibitors in chronic kidney disease: cardiorenal outcomes, safety, and implementation in primary care2026